Mobile

A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may b...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-001097-15

A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments including subjects who may be missing part of their chromosome 17 identified as 17p deletion, or TP53 gene mutation; or subjects who have received prior treatment with a B-Cell receptor inhibitor

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study to evaluate the impact of venetoclax monotherapy on the quality of life of subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 gene mutations or in CLL subjects who have received prior B-Cell receptor inhibitor (BCRi) therapy using the European Organization of Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30).

Critère d'inclusion

  • Chronic lymphocytic leukemia

Liens